Results 31 to 40 of about 616 (213)

Interleukin‐5, Eosinophils, and Interleukin‐5 Pathway Inhibitors in Eosinophilic Granulomatosis With Polyangiitis

Arthritis &Rheumatology, EarlyView.
Interlukin‐5 (IL‐5) plays a crucial role in the pathogenesis of eosinophilic granulomatosis with polyangiitis (EGPA) by promoting eosinophil differentiation, activation, and survival. We present here a typical case of EGPA in which treatment with IL‐5 pathway inhibitors is prescribed, showing to be beneficial for the patient.
Alvise Berti, Christian Pagnoux
wiley   +1 more source

Short‐Term Prophylaxis in Odontostomatological, Maxillofacial and ENT Procedures in Patients with Hereditary Angioedema Due to C1‐Inhibitor Deficiency [PDF]

, 2017
Oestrogens, trauma, infections or stress has been described as triggers for angioedema (AE) attacks in patients with hereditary angioedema due to C1-inhibitor deficiency (C1-INH-HAE).
Caballero, Teresa, Jurado-Palomo, Jesús
core   +2 more sources

Clinical periodontal diagnosis

Periodontology 2000, EarlyView., 2023
Abstract Periodontal diseases include pathological conditions elicited by the presence of bacterial biofilms leading to a host response. In the diagnostic process, clinical signs such as bleeding on probing, development of periodontal pockets and gingival recessions, furcation involvement and presence of radiographic bone loss should be assessed prior ...
Giovanni E. Salvi, Andrea Roccuzzo, Jean‐Claude Imber, Alexandra Stähli, Björn Klinge, Niklaus P. Lang   +5 more
wiley   +1 more source

Icatibant, An Inhibitor Of Bradykinin Receptor 2, For Hereditary Angioedema Attacks: Prospective Experimental Single-cohort Study. [PDF]

, 2015
Hereditary angioedema (HAE) with C1 inhibitor deficiency manifests as recurrent episodes of edema involving the skin, upper respiratory tract and gastrointestinal tract. It can be lethal due to asphyxia.
Campos, Regis Albuquerque, Cordeiro, Elisabete, França, Alfeu Tavares, Fusaro, Gustavo, Grumach, Anete Sevciovic, Malheiros, Teresinha, Mansour, Elie, Mello, Yara Ferreira, Serpa, Faradiba Sarquis, Toledo, Eliana, Valle, Solange Oliveira Rodrigues   +10 more
core  

Intravenous lanadelumab for the treatment of moderately ill COVID‐19 patients

British Journal of Clinical Pharmacology, EarlyView.
Aims Kallikrein‐kinin system (KKS) dysregulation is hypothesized to play a pathogenetic role in COVID‐19‐associated pulmonary oedema. To investigate the efficacy and safety of intravenous lanadelumab, a monoclonal antibody that inhibits plasma kallikrein, in COVID‐19, we conducted a phase 2, open‐label, randomized‐controlled, proof‐of‐concept ...
Job J. Engel, Christine van Linge, W. Joost Wiersinga, Ilse J. E. Kouijzer, Quirijn de Mast, Robert‐Jan Hassing, Danique J. H. Huijbens, Helen L. Leavis, Roger Schutgens, Coen Maas, Kit C. B. Roes, Frank L. van de Veerdonk, Roger Brüggemann   +12 more
wiley   +1 more source

Analysis of interstitial lung disease in pharmacovigilance databases: Coding challenges and interpretation biases—An update

British Journal of Clinical Pharmacology, EarlyView.
Aim Clinically, interstitial lung disease (ILD) is a heterogeneous group of respiratory disorders. Due to their low incidence, pharmacovigilance database analysis is useful to detect them. Precise diagnosis is challenging as well as coding in these databases. Query criteria are among the key elements for a good signal detection.
Romane Freppel, Adeline Benis, Philippe Bonniaud, Jean‐Luc Faillie, Aurélie Grandvuillemin   +4 more
wiley   +1 more source

Berotralstat for long-term prophylaxis of hereditary angioedema in Japan: Parts 2 and 3 of the randomized APeX-J Phase III trial

World Allergy Organization Journal
Background: Berotralstat is a once-daily oral inhibitor of plasma kallikrein for the prophylaxis of hereditary angioedema (HAE) in patients ≥12 years. APeX-J aimed to evaluate the efficacy and safety of berotralstat in Japan.
Daisuke Honda, MD, PhD, Michihiro Hide, MD, PhD, Tomoo Fukuda, MD, PhD, Keisuke Koga, MD, PhD, Eishin Morita, MD, PhD, Shinichi Moriwaki, MD, Yoshihiro Sasaki, MD, PhD, Yusuke Suzuki, MD, PhD, Phil Collis, PhD, Douglas T. Johnston, DO, Dianne Tomita, MPH, Bhavisha Desai, PharmD, Isao Ohsawa, MD, PhD   +12 more
doaj   +1 more source

Evaluating the (comparative) safety profile of the novel oral polio vaccine type 2 using individual case safety reports in VigiBase

British Journal of Clinical Pharmacology, EarlyView.
Aim Novel oral polio vaccine type 2 (nOPV2) was used under the WHO emergency use listing for circulating vaccine‐derived polio virus (cVDPV) outbreaks from 2021 to 2023. We assessed nOPV2 adverse events following immunization (AEFIs) and compared its safety profile to other vaccines using VigiBase.
Comfort Kunak Ogar, Malede Mequanent Sisay, Leonardo Roque‐Pereira, Christine Leopold, Patrick C. Souverein, Aukje K. Mantel‐Teeuwisse, Marie L. De Bruin   +6 more
wiley   +1 more source

“Effects of High‐Intensity Ultrasound on the Structural, Technofunctional, and Allergenic Properties of Groundnut (Arachis hypogaea L.) Protein Isolates: A Review”

Food Chemistry International, EarlyView.
ABSTRACT The growing global demand for sustainable, nutritionally balanced protein sources has intensified interest in plant‐derived proteins, particularly those derived from oilseeds such as groundnut (Arachis hypogaea L.). However, although groundnut protein isolates (GPIs) have high nutritional quality, they exhibit limitations in technofunctional ...
Ángel Efraín Rodríguez Rivera, Kevin Ulises López Martír, Judith Esmeralda Urías Silvas, Juan Alberto Resendiz Vazquez, Raúl Delgado Delgado, María Soledad Córdova Aguilar, Antonio Hidalgo Millan   +6 more
wiley   +1 more source

Angioedema: ACE-Inhibitors Adverse Reaction [PDF]

, 2017
This is a poster presentation about angioedema caused by Angiotensin-converting enzyme (ACEI or ACE Inhibitors). Angiotensin-converting enzyme inhibitor (ACEI) medications are one of the leading causes of angioedema in the United States, also known as ...
VanDyne, Jesse
core   +1 more source